Page 2 - Robert Ajer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 34.47% from the stock’s previous close. Several […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.75-2.95 for the period, compared to the consensus earnings per share estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. […]

Fort Washington Investment Advisors Inc. OH lowered its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,165,589 shares of the biotechnology company’s stock after selling 142,656 shares […]

Andra AP fonden lowered its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 18.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 72,200 shares of the biotechnology company’s stock after selling 16,700 shares during the quarter. Andra AP fonden’s holdings […]